What is William Blair’s Estimate for Xencor FY2025 Earnings?

Xencor, Inc. (NASDAQ:XNCR) – Research analysts at William Blair upped their FY2025 earnings estimates for shares of Xencor in a research report issued on Wednesday, November 5th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of ($1.90) per share for the year, up from their prior estimate of ($2.83). The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor’s Q4 2025 earnings at ($0.75) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at ($2.67) EPS and FY2028 earnings at ($2.78) EPS.

Several other analysts have also commented on the stock. Barclays raised shares of Xencor from an “underweight” rating to an “overweight” rating and lifted their price objective for the stock from $6.00 to $23.00 in a research report on Wednesday, October 29th. Wells Fargo & Company lowered their price target on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research note on Thursday, November 6th. Royal Bank Of Canada raised their target price on Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Bank of America lowered Xencor from a “buy” rating to a “neutral” rating and lowered their target price for the company from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.63.

Xencor Price Performance

NASDAQ XNCR opened at $13.74 on Monday. The company has a fifty day moving average price of $11.82 and a 200-day moving average price of $9.70. The firm has a market cap of $981.17 million, a price-to-earnings ratio of -5.72 and a beta of 0.99. Xencor has a 1 year low of $6.92 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.64. The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period last year, the business posted ($0.71) EPS.

Institutional Trading of Xencor

A number of institutional investors have recently made changes to their positions in XNCR. State of Wyoming bought a new stake in shares of Xencor in the first quarter worth about $34,000. CWM LLC lifted its holdings in Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 2,231 shares during the period. Hantz Financial Services Inc. grew its position in shares of Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,156 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares during the last quarter. Finally, Farther Finance Advisors LLC purchased a new position in shares of Xencor during the third quarter valued at approximately $44,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.